在一名患有肾源性系统性纤维化的患者中钆与去铁胺的螯合作用。
Chelation of gadolinium with deferoxamine in a patient with nephrogenic systemic fibrosis.
作者信息
Leung Nelson, Pittelkow Mark R, Lee Christine U, Good Jonathan A, Hanley Matthew M, Moyer Thomas P
机构信息
Division of Nephrology and Hypertension.
Department of Dermatology.
出版信息
NDT Plus. 2009 Aug;2(4):309-11. doi: 10.1093/ndtplus/sfp042. Epub 2009 Apr 23.
Abstract
A 65-year-old female with biopsy-confirmed nephrogenic systemic fibrosis (NSF) received a kidney transplantation. Despite good kidney function, her symptoms continued to progress. Deferoxamine was administered intramuscularly at 500 mg/day and later 1000 mg/day after 1 week with no adverse effects. Urine excretion of gadolinium increased from 6.0 μg/day to 11.6 μg/day and subsequently to 13.0 μg/day with 500 mg/day and 1000 mg/day of deferoxamine, respectively. Serum levels, however, remain unchanged from 1.7 ng/ml to 1.4 ng/ml. Although chelation therapy may have a role in the treatment of NSF, deferoxamine is too weak and a stronger chelator is needed.
摘要
一名经活检确诊为肾源性系统性纤维化（NSF）的65岁女性接受了肾脏移植。尽管肾功能良好，但其症状仍持续进展。给予去铁胺肌肉注射，初始剂量为500mg/天，1周后增加至1000mg/天，未出现不良反应。使用500mg/天和1000mg/天去铁胺时，钆的尿排泄量分别从6.0μg/天增加至11.6μg/天，随后又增加至13.0μg/天。然而，血清水平保持不变，从1.7ng/ml降至1.4ng/ml。尽管螯合疗法可能在NSF治疗中发挥作用，但去铁胺的螯合作用较弱，需要更强效的螯合剂。
相似文献
1
Chelation of gadolinium with deferoxamine in a patient with nephrogenic systemic fibrosis.在一名患有肾源性系统性纤维化的患者中钆与去铁胺的螯合作用。
NDT Plus. 2009 Aug;2(4):309-11. doi: 10.1093/ndtplus/sfp042. Epub 2009 Apr 23.
2
Tissue gadolinium deposition and fibrosis mimicking nephrogenic systemic fibrosis (NSF)-subclinical nephrogenic systemic fibrosis?组织钆沉积和纤维化类似于肾源性系统性纤维化（NSF）-亚临床肾源性系统性纤维化？
J Am Acad Dermatol. 2010 Feb;62(2):337-42. doi: 10.1016/j.jaad.2009.04.010. Epub 2009 Nov 24.
3
Evidence Suggesting a Role of Iron in a Mouse Model of Nephrogenic Systemic Fibrosis.铁在小鼠肾源性系统性纤维化模型中的作用证据
PLoS One. 2015 Aug 25;10(8):e0136563. doi: 10.1371/journal.pone.0136563. eCollection 2015.
4
A Systematic Review of 639 Patients with Biopsy-confirmed Nephrogenic Systemic Fibrosis.经活检证实的 639 例肾源性系统性纤维化患者的系统评价。
Radiology. 2019 Aug;292(2):376-386. doi: 10.1148/radiol.2019182916. Epub 2019 Jul 2.
5
Nephrogenic systemic fibrosis: A 15-year retrospective study at a single tertiary care center.肾源性系统性纤维化：单中心 15 年回顾性研究。
J Am Acad Dermatol. 2017 Aug;77(2):235-240. doi: 10.1016/j.jaad.2017.02.003. Epub 2017 Mar 18.
6
Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.基于钆的造影剂暴露、肾源性系统性纤维化以及组织中的钆检测
AJR Am J Roentgenol. 2008 Apr;190(4):1060-8. doi: 10.2214/AJR.07.2822.
7
Gadolinium-induced nephrogenic systemic fibrosis in a patient with an acute and transient kidney injury.一名急性短暂性肾损伤患者发生钆剂所致的肾源性系统性纤维化。
Br J Dermatol. 2008 Mar;158(3):607-10. doi: 10.1111/j.1365-2133.2007.08369.x. Epub 2007 Dec 11.
8
The debate between gadolinium versus erythropoietin in a renal transplant patient with nephrogenic systemic fibrosis.肾移植患者伴肾性系统性纤维化中钆剂与促红细胞生成素的争论。
J Nephrol. 2013 Jan-Feb;26(1):48-54. doi: 10.5301/jn.5000159.
9
Risk of nephrogenic systemic fibrosis in liver transplantation patients.肝移植患者发生肾源性系统性纤维化的风险。
AJR Am J Roentgenol. 2011 Sep;197(3):658-62. doi: 10.2214/AJR.10.5976.
10
Erythema nodosum masking nephrogenic systemic fibrosis as initial skin manifestation.结节性红斑掩盖了以皮肤为首发表现的肾源性系统性纤维化。
BMC Nephrol. 2017 Jul 24;18(1):249. doi: 10.1186/s12882-017-0666-7.
引用本文的文献
1
Gadolinium in Medical Imaging-Usefulness, Toxic Reactions and Possible Countermeasures-A Review.医学影像学中的钆——用途、毒副作用及可能的对策：综述。
Biomolecules. 2022 May 24;12(6):742. doi: 10.3390/biom12060742.
2
Changes in tissue gadolinium biodistribution measured in an animal model exposed to four chelating agents.在暴露于四种螯合剂的动物模型中测量的组织钆生物分布变化。
Jpn J Radiol. 2019 Jun;37(6):458-465. doi: 10.1007/s11604-019-00835-1. Epub 2019 Mar 30.
3
Removal of a gadolinium based contrast agent by a novel sorbent hemoperfusion in a chronic kidney disease (CKD) rodent model.新型吸附剂血液灌流在慢性肾脏病（CKD）啮齿动物模型中清除钆基造影剂。
Sci Rep. 2019 Jan 24;9(1):709. doi: 10.1038/s41598-018-37348-2.
4
Urinary Gadolinium Levels After Contrast-Enhanced MRI in Individuals with Normal Renal Function: a Pilot Study.正常肾功能个体接受对比增强 MRI 后的尿钆水平：一项初步研究。
J Med Toxicol. 2019 Apr;15(2):121-127. doi: 10.1007/s13181-018-0693-1. Epub 2018 Dec 12.
5
Evaluating the Patient with Reported Gadolinium-Associated Illness.评估报告的钆相关疾病患者。
J Med Toxicol. 2019 Jan;15(1):36-44. doi: 10.1007/s13181-018-0689-x. Epub 2018 Nov 29.
6
Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms.钆基造影剂毒性：已知及推测机制的综述
Biometals. 2016 Jun;29(3):365-76. doi: 10.1007/s10534-016-9931-7. Epub 2016 Apr 6.
本文引用的文献
1
Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis.伊马替尼治疗可预防系统性硬化症不同临床前模型中的纤维化，并促使已形成的纤维化消退。
Arthritis Rheum. 2009 Jan;60(1):219-24. doi: 10.1002/art.24186.
2
Imatinib in the treatment of nephrogenic systemic fibrosis.伊马替尼治疗肾源性系统性纤维化
Am J Kidney Dis. 2009 Jan;53(1):129-32. doi: 10.1053/j.ajkd.2008.08.029. Epub 2008 Nov 13.
3
Combination treatment with plasmapheresis and sirolimus does not seem to benefit nephrogenic systemic fibrosis.血浆置换与西罗莫司联合治疗似乎对肾源性系统性纤维化并无益处。
Int J Artif Organs. 2008 Oct;31(10):913-4. doi: 10.1177/039139880803101009.
4
Imatinib mesylate treatment of nephrogenic systemic fibrosis.甲磺酸伊马替尼治疗肾源性系统性纤维化
Arthritis Rheum. 2008 Aug;58(8):2543-8. doi: 10.1002/art.23696.
5
Nephrogenic systemic fibrosis: early recognition and treatment.肾源性系统性纤维化：早期识别与治疗
Semin Dial. 2008 Mar-Apr;21(2):123-8. doi: 10.1111/j.1525-139X.2007.00399.x. Epub 2008 Jan 23.
6
Patient characteristics and risk factors for nephrogenic systemic fibrosis following gadolinium exposure.钆暴露后发生肾源性系统性纤维化的患者特征及危险因素。
Semin Dial. 2008 Mar-Apr;21(2):135-9. doi: 10.1111/j.1525-139X.2007.00406.x. Epub 2008 Jan 23.
7
Treatment of nephrogenic systemic fibrosis: limited options but hope for the future.肾源性系统性纤维化的治疗：选择有限但未来仍有希望。
Semin Dial. 2008 Mar-Apr;21(2):155-9. doi: 10.1111/j.1525-139X.2007.00407.x. Epub 2008 Jan 23.
8
Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis.钆在患有肾源性系统性纤维化的患者组织中可被检测到。
J Am Acad Dermatol. 2007 Jan;56(1):21-6. doi: 10.1016/j.jaad.2006.10.047. Epub 2006 Nov 9.
9
Nephrogenic fibrosing dermopathy: a comprehensive review for the dermatologist.肾源性纤维化皮肤病：皮肤科医生的全面综述
Am J Clin Dermatol. 2006;7(4):237-47. doi: 10.2165/00128071-200607040-00005.
10
Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis.钆双胺注射液在严重肾功能不全患者以及接受血液透析或持续性非卧床腹膜透析患者中的药代动力学。
Acad Radiol. 1998 Jul;5(7):491-502. doi: 10.1016/s1076-6332(98)80191-8.
Zotero 插件